Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Sham in Macular Edema Secondary to CRVO
NCT00567697Phase 3Completed
- Sponsor
- Aleris Helse AS
- Start
- Mar 2007
- Primary completion
- Oct 2008
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in macular edema, central retinal vein occlusion (CRVO), sponsored by Aleris Helse AS. Started Mar 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edemacentral retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT00567697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00567697.